MESO Stock Latest News

PremiumThe Fly

Mesoblast Details April Equity Issuance Moves and Director Share Purchases

1M ago

EVC

RUM

PremiumCompany Announcements

2M ago

PremiumThe Fly

2M ago

RUM

YSS

PremiumThe FlyMesoblast acquires chimeric antigen receptor platform technology

2M ago

The Fly

Mesoblast receives IND clearance from FDA for Ryoncil trial

2M ago

The Fly

Mesoblast reports $30.3M in Ryoncil sales in March quarter

2M ago

Mesoblast reports March quarter Ryoncil sales of $30.3M

PremiumThe Fly

2M ago

PremiumThe Fly

Mesoblast Grants New Director Options Following 2025 AGM Approvals

3M ago

NVS

PEW

PremiumCompany Announcements

3M ago

Mesoblast Discloses Director Gregory George’s Share and ADS Purchases in Early March 2026

PremiumCompany Announcements

3M ago

PremiumThe FlyLargest borrow rate increases among liquid names

3M ago

KDK

MPT

Mesoblast Earnings Call: Ryoncil Momentum Meets Rising Costs

Company Announcements

Mesoblast Earnings Call: Ryoncil Momentum Meets Rising Costs

4M ago

Company Announcements

Mesoblast Sets Webcast to Present Half-Year 2025 Results and Corporate Update

4M ago

Mesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial

PremiumCompany Announcements

4M ago

Mesoblast Lifts Ryoncil Revenues, Secures Cheaper Credit and Advances Late-Stage Cell Therapy Pipeline

PremiumCompany Announcements

5M ago

Mesoblast Reports 84% Survival in Early Real‑World Use of Ryoncil for Pediatric SR‑aGvHD

PremiumCompany Announcements

5M ago

PremiumThe Fly

5M ago

GDS

MMM

PremiumCompany AnnouncementsMesoblast Wins FDA Backing on Pain and Opioid-Reduction Data for Rexlemestrocel-L in Chronic Low Back Pain

5M ago

The Fly

Mesoblast received FDA feedback on potential BLA for rexlemestrocel-L

5M ago

Company Announcements

Mesoblast Trims Option Overhang After Late-2025 Lapse of 1.45 Million Unquoted Options

5M ago